Vela Analytics can create concise, evidence-based in-house reports that help customers with the information to make timely, informed decisions about possible treatment options
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
USFDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
The investment will accelerate the overall Sarclisa development program
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey
Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
Tislelizumab is now approved for seven indications in China
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
Subscribe To Our Newsletter & Stay Updated
